MetLife Stock: Shares Decline by 3.58% Following Brokerage Downgrade
The trading session on January 7th saw a significant correction for the American insurer. The stock faced considerable selling pressure even as the US indices were trending positively. This downward movement came in the wake of a downgrade by a leading brokerage.
Market Performance and Stock Details
MetLife closed at $78.27 on Tuesday, marking a decline of 3.58% from the previous session. This downturn went against the grain of the American market, with the S&P 500 gaining 0.36% during the same period to reach 6,740.28 points. Trading volumes were recorded at 4.37 million shares, representing 0.66% of the insurer's market capitalization, indicating relatively moderate activity on the stock. Over the week, the stock has decreased by 0.85%, reflecting an unfavorable underlying trend. Over the past year, the stock has fallen by 4.71%, a stark contrast to the 18.33% rise of the benchmark S&P 500 index over the same period. This performance gap of over 23 percentage points highlights the specific challenges faced by the insurer in an otherwise buoyant US market.
Brokerage Downgrade and Market Impact
The correction observed on Tuesday followed a recommendation revision published the day before by Evercore ISI. The brokerage downgraded its rating on the stock from 'outperform' to 'in-line', along with a reduction in the price target from $108 to $97. Despite this downgrade, the new target still suggests an upside potential relative to the last closing price. Evercore ISI analysts cite several reasons for their repositioning, including a valuation that no longer offers a comparative advantage over mid-cap peers in the sector, amid downward revisions of earnings estimates. The brokerage also highlighted the insurer's narrow reinvestment spreads on government bonds and a commercial mortgage loan portfolio deemed more exposed than those of its competitors. These factors, according to them, limit the potential for earnings appreciation and could impact valuation in the event of deteriorating credit conditions or the commercial real estate market. However, the consensus among analysts remains largely positive, with 13 buy recommendations out of 17 and a median target of $94.50 according to compiled data.
